Medical stocks continued to decline in the afternoon, with dongfulong falling more than 15%

Big Pharma CCHT’s Domination Unlikely to Fade Soon Despite Official Bulk Buying

The producer of long-acting growth hormone acupunctures, vaccines and other drugs, looks set to offset the effects of so-called “centralized procurement” on its product prices with more aggressive expansion into private hospitals. So far, its monopoly appears unshakable, but with more competitors upping the stakes, how long will it last?

Surgerii Robotics: Single-Port Surgical Robots Poised to Transform Surgery

The worldwide surgical robotic market is expected to grow at a booming CAGR of 5.8% during 2022 to 2030, rising from USD 5.05 billion in 2022 to USD 21.41 billion in 2030. Of which, the single-port surgical robots that result in less pain, fewer scars, and quicker recovery, have tremendous up potential.

Pulnovo Medical: Chinese Medical Device Companies are Making Their Voices Heard Globally

‘Chinese medical device companies, represented by Pulnovo Medical, have always pursued medical innovation under the support of policies and capital. They have increasingly improved their technical innovation, strategic planning, and product competitiveness. Navigating the way through a dynamic, ever-changing market, Chinese medical device companies are making their voices heard in the global market.’

AI Protein Design Platform MoleculeMind Completed Over CNY 100 Mn Strategic Round Funding

Synthetic biology leader Cathay Biotech seeks a more efficient AI-driven manufacturing process

Compound Steep Pulse Device Developer REMD Nets Over CNY 100 Mn in Series A+

The leader in irreversible electroporation technology plans to expand the use of technology in various indications